Loading data
BIOXNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 335.11 m USD | 464.78 m USD | 420.06 m USD | 334.84 m USD |
| Cost of revenue | 203.42 m USD | 278.22 m USD | 235.46 m USD | 208.36 m USD |
| Gross profit | 131.68 m USD | 186.56 m USD | 184.6 m USD | 126.48 m USD |
| Research and development expense | 14.91 m USD | 17.18 m USD | 15.35 m USD | 6.95 m USD |
| Selling, general and administrative expense | 123.11 m USD | 123.69 m USD | 113 m USD | 77.48 m USD |
| Operating profit | -2.24 m USD | 45.85 m USD | 54.18 m USD | 39.87 m USD |
| Interest expense | 28.84 m USD | 26.87 m USD | 23.79 m USD | 17.93 m USD |
| Profit before tax | -57.57 m USD | 11.07 m USD | 19.11 m USD | 14.06 m USD |
| Income tax expense | 1.27 m USD | 3.78 m USD | -1.07 m USD | 17.97 m USD |
| Net income (reported basis) | -58.85 m USD | 7.29 m USD | 20.17 m USD | -3.91 m USD |
| Net income attributable to owners of the parent | -55.42 m USD | 4.28 m USD | 18.78 m USD | -7.2 m USD |
| Basic earnings per share | -0.88 USD/share | 0.07 USD/share | 0.3 USD/share | -0.17 USD/share |
| Diluted earnings per share | -0.88 USD/share | 0.07 USD/share | 0.3 USD/share | -0.17 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.